Securities code: Hvsen Biotechnology Co.Ltd(300871) securities abbreviation: Hvsen Biotechnology Co.Ltd(300871) Announcement No.: 2022020 convertible bond Code: 123132 convertible bond abbreviation: Huisheng convertible bond
Hvsen Biotechnology Co.Ltd(300871)
On the closing of some projects invested by raising shares in the initial public offering and raising the surplus funds
Announcement of permanent replenishment of working capital
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Hvsen Biotechnology Co.Ltd(300871) (hereinafter referred to as “the company” or “the company”) held the 23rd Meeting of the second board of directors and the 20th meeting of the second board of supervisors on March 10, 2022, deliberated and adopted the proposal on closing some projects invested by raising shares through initial public offering and permanently replenishing the surplus raised funds with working capital, The projects of “Taigou production base with an annual output of 1.6 million tons” and “Taigou production base with an annual production capacity of 1.6 million tons” are approved, And permanently replenish the working capital with the balance raised as of February 28, 2022, totaling 973177 million yuan (including the unpaid project balance, the specific amount shall be subject to the bank settlement balance on the day of fund transfer out, the same below) for the production and operation activities of the company. Meanwhile, relevant personnel of the company are authorized to handle the cancellation of the special account for raised funds, and the corresponding supervision agreement for raised funds is terminated accordingly.
According to relevant laws and regulations such as the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022), the Listing Rules of GEM stocks of Shenzhen Stock Exchange, the guidelines for the self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM, and the company’s raised funds management system The matter still needs to be submitted to the general meeting of shareholders of the company for deliberation. The relevant information is hereby announced as follows:
1、 Basic information of raised funds
(I) actual amount of raised funds and time of fund arrival
With the approval of registration of Hvsen Biotechnology Co.Ltd(300871) initial public offering issued by China Securities Regulatory Commission (zjxk [2020] No. 1586), the company publicly issued 27700000 ordinary shares in RMB to the public in August 2020, with a par value of 1.00 yuan per share, an issue price of 33.61 yuan per share and a total raised capital of 93099700000 yuan, After deducting 6336772639 yuan of recommendation and underwriting fee (excluding tax), the raised fund is 86762927361 yuan. In addition, after deducting 1691675281 yuan of issuance expenses excluding tax, such as audit and verification fees, lawyer fees, information disclosure fees and notarization fees, the net amount of raised funds is 85071252080 yuan. All the above raised funds were received on August 17, 2020 and verified by Zhongshen Zhonghuan Certified Public Accountants (special general partnership), and a capital verification report of Zhonghuan Yanzi [2020] No. 010051 was issued.
(II) investment plan of raised funds
The plan for the use of the net funds raised by the company’s initial public offering is as follows:
Unit: 10000 yuan
No. project name total investment raised funds
Investment amount
1 Xingou base powder / powder / premix automatic production base construction project 320 Shenzhen Sed Industry Co.Ltd(000032) 00000
2. R & D and quality inspection center construction project 7 Shenzhen Quanxinhao Co.Ltd(000007) 00000
3. Construction project of 1600t / a tylosin fermentation production base 7 Shenzhen Quanxinhao Co.Ltd(000007) 00000
4. Construction project of traditional Chinese medicine extraction and preparation production line 6 Shenzhen Zhenye(Group)Co.Ltd(000006) 00000
5. Supplementary working capital 7 Shenzhen Quanxinhao Co.Ltd(000007) 00000
6. Over raising: tylosin project with an annual output of 1000 tons 38 China Vanke Co.Ltd(000002) 607125
Total 97 China High-Speed Railway Technology Co.Ltd(000008) 507125
2、 Deposit and management of raised funds
(I) management of raised funds
In order to standardize the management of the company’s raised funds, improve the use efficiency of the raised funds and effectively protect the legitimate rights and interests of shareholders, In accordance with the company law, the securities law, the Interim Measures for the administration of initial public offering and listing on the gem, the measures for the administration of securities issuance of listed companies, the Listing Rules of Shenzhen Stock Exchange on the gem, the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of funds raised by listed companies (revised in 2022), and The management system of Hvsen Biotechnology Co.Ltd(300871) raised funds (hereinafter referred to as the “management system”) is formulated in combination with the actual situation of the company, such laws, regulations, rules and normative documents as the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM, as well as the relevant provisions of the articles of association.
According to the requirements of the management system and in combination with the company’s business needs, the company implements a special account for the funds raised by the initial public offering, and implements strict approval procedures for the use of the raised funds to ensure that the special funds are used for special purposes.
Upon deliberation and approval at the 8th meeting of the second board of directors of the company, on August 27, 2020, the company, together with the sponsor Haitong Securities Company Limited(600837) (hereinafter referred to as ” Haitong Securities Company Limited(600837) “) and Hankou Bank Co., Ltd. Wuchang sub branch, China Merchants Bank Co.Ltd(600036) Wuhan Dongxihu sub branch, China Citic Bank Corporation Limited(601998) Wuhan Branch Agricultural Bank Of China Limited(601288) Yingcheng sub branch signed the tripartite supervision agreement on the funds raised by initial public offering; Upon deliberation and approval at the 9th meeting of the second board of directors, on September 10, 2020, the company and its wholly-owned subsidiary Hubei Hvsen Biotechnology Co.Ltd(300871) Technology Co., Ltd. (hereinafter referred to as “Hubei Huisheng”) signed the tripartite supervision agreement on the raised funds from initial public offering of shares with the sponsor Haitong Securities Company Limited(600837) and Agricultural Bank Of China Limited(601288) Yingcheng branch as the same party; Upon deliberation and approval at the 11th meeting of the second board of directors of the company, on November 17, 2020, the company, Hubei Huisheng, together with the sponsor Haitong Securities Company Limited(600837) and China Merchants Bank Co.Ltd(600036) Wuhan Dongxihu sub branch signed the four party supervision agreement on raised funds.
There is no significant difference between the contents of the above regulatory agreement and the model regulatory agreement of Shenzhen Stock Exchange, and the company has strictly complied with the raised funds.
(II) storage of raised funds in special account
As of February 28, 2022, the storage of funds raised by the company’s initial public offering is as follows:
Serial number account name deposit bank’s balance on the deadline for raising funds (Note 1) special account number (RMB)
1 Wuhan Hvsen Biotechnology Co.Ltd(300871) kehankou Bank Co., Ltd. has 27501010 Innuovo Technology Co.Ltd(000795) 775736461 current technology Co., Ltd. Wuchang sub branch
Wuhan Hvsen Biotechnology Co.Ltd(300871) branch China Merchants Bank Co.Ltd(600036) Co., Ltd
2 Technology Co., Ltd. Wuhan Dongxi 12790620361060527444.04 current Lake sub branch
Wuhan Hvsen Biotechnology Co.Ltd(300871) branch China Citic Bank Corporation Limited(601998) Co., Ltd
Wuhan Dongxihu Branch Technology Co., Ltd. 11574417430103
Wuhan Hvsen Biotechnology Co.Ltd(300871) Branch China Agricultural Bank Of China Limited(601288) shares
4 Technology Co., Ltd. Yingcheng 1752530104 Cccg Real Estate Corporation Limited(000736) 973419710 current city sub branch
Hubei Hvsen Biotechnology Co.Ltd(300871) Branch China Agricultural Bank Of China Limited(601288) shares
5 Technology Co., Ltd. Yingcheng 1752530104 Apeloa Pharmaceutical Co.Ltd(000739) 390948275 current city sub branch
Hubei Hvsen Biotechnology Co.Ltd(300871) branch China Merchants Bank Co.Ltd(600036) Co., Ltd
6 Technology Co., Ltd. Wuhan Dongxi 127906403310905292889350 current Lake sub branch
Total 10403481904
Note 1: the account with zero balance will be cancelled after it is deliberated and approved by the general meeting of shareholders and the surplus raised funds are transferred out
3、 Status of the projects invested with raised funds settled this time
(I) utilization and savings of the raised funds of the closed project
As of February 28, 2022, the company’s “Xingou base powder / powder / premix automatic production base construction project” has raised 862633 million yuan, accounting for 26.96% of the net funds raised by the project; The surplus raised funds of “Xingou base – R & D and quality inspection center construction project” are 110275 million yuan, accounting for 15.75% of the net funds raised by the project; The surplus fund raised by the “construction project of tylosin fermentation production base with an annual output of 160 tons” is 26900 yuan, accounting for 0.04% of the net fund raised by the project. The details are as follows:
Monetary unit: RMB 10000
Committed investment project total committed investment actual investment raised funds investment progress surplus raised funds (Note 2)
Xingou base – powder / powder / premix from 32 China Vanke Co.Ltd(000002) 337367 73.04% 862633 automation production base construction project
Xingou base – R & D and quality inspection center 7 Shenzhen Fountain Corporation(000005) 89725 84.25% 110275 construction project
1600t / a tylosin fermentation 7 Shenzhen Zhenye(Group)Co.Ltd(000006) 99731 99.96% 2.69 production base construction project
Total 460 China Union Holdings Ltd(000036) 26823 78.84% 973177
Note 2: the surplus raised funds include the outstanding balance of the project, and the actual transfer out amount shall be subject to the balance of the bank account on the day when the special account for raised funds is finally transferred into the self owned fund account; The interest and financial income of the idle raised funds of the above-mentioned raised investment projects shall be carried forward uniformly after all the raised investment projects of the company’s initial public offering of shares are carried forward
(II) main reasons for the fund savings of the project invested with raised funds
1. The balance of this raised investment project includes the unpaid equipment procurement contract and engineering construction contract quality guarantee deposit of “Xingou base – powder / powder / premix automatic production base construction project”, “Xingou base – R & D and quality inspection center construction project” and “1600t / a tylosin fermentation production base construction project”. Due to the long payment period of the balance of these contracts, The surplus amount will be used to supplement the working capital for the company’s daily production and operation, which is conducive to improving the efficiency of capital use and avoiding long-term idleness of funds. common
